Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

3D-printed ankle braces may help with balance, foot pain: Study

The use of 3D-printed, customized ankle braces may improve balance and reduce foot pain in people with Charcot-Marie-Tooth (CMT) disease, according to a recent pilot study in New Zealand. Although patients reported variable levels of comfort and satisfaction, they generally said the braces were moderately comfortable, and were moderately…

Endgame campaign surpasses $10M raised for CMT1A treatments

The CMT Research Foundation (CMTRF) has raised more than its $10 million goal for the Endgame campaign to support research toward treatments for Charcot-Marie-Tooth disease type 1A (CMT1A). The foundation announced the results at the annual Global CMT Research Convention, which took place Sept. 26-28 in…

Cochlear implants for CMT may improve hearing, quality of life

Cochlear implants are a safe and reliable way to improve hearing, speech, and quality of life for people with Charcot-Marie-Tooth disease (CMT), according to a case series. This study provides “more evidence supporting the potential benefit of cochlear implantation among CMT patients,” researchers wrote. “The present analysis is also…

CMTRF funds Vanderbilt research on potential CMT1A treatments

The CMT Research Foundation (CMTRF) has invested in a project at Vanderbilt University School of Medicine Basic Sciences for potential new treatments for Charcot-Marie-Tooth disease type 1A (CMT1A). The project will be conducted by Charles Sanders, PhD, a biochemistry and medicine professor and vice dean at Vanderbilt. Sanders’…

Oryzon picks HDAC6 inhibitor to develop as potential CMT treatment

Oryzon Genomics has chosen ORY-4001, a selective histone deacetylase 6 (HDAC6) inhibitor, for clinical development as a potential treatment for Charcot-Marie-Tooth (CMT) disease and other neurological conditions. HDAC6 enzyme inhibitors have shown promise for CMT, amyotrophic lateral sclerosis, and other neurological diseases, Oryzon states. ORY-4001 will now…

Measure of myelin damage may aid demyelinating CMT diagnosis

A measure of the distribution of demyelination — myelin loss — may improve the diagnosis of demyelinating Charcot-Marie-Tooth disease (CMT) and better distinguish it from a related rare disease, a study in Japan found. Specifically, the compound muscle action potential (CMAP) duration ratio was significantly lower in people with CMT…

Joint Research Grant From MDA, CMTRF Will Focus on CMT4B1

The Muscular Dystrophy Association (MDA) and the Charcot-Marie-Tooth Research Foundation (CMTRF) have awarded a joint research grant that will examine cellular changes in Charcot-Marie-Tooth (CMT) disease with aberrant myelin. The research team led by Alessandra Bolino, Ph.D., at San Raffaele Hospital, Italy received a $263,450 grant for…